CD8A and neoplasm: In this regard, interestingly, the long‐term survival after nivolumab treatment (>500 days) was correlated with higher frequencies of pretreatment CD4+CD62Llow cells (activated memory cells) compared with short‐term response (<500 days),58 indicating that activation of both CD8+ and CD4+ T cells is important for tumour immunity after ICB.